769895-06-9

Basic information

• Product Name: 1,4,5,6-TETRAHYDROPYRROLO[3,4-C]PYRAZOLE
• Synonyms: 1,4,5,6-TETRAHYDROPYRROLO[3,4-C]PYRAZOLE;1,4,5,6-Teterahydropyrazolo[3,4-c]pyrazole
• CAS NO: 769895-06-9
• Molecular Formula: C₅H₇N₃
• Molecular Weight: 109.13
• Mol File: 769895-06-9.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 303.287 °C at 760 mmHg
• Flash Point: 137.224 °C
• Appearance: /
• Density: 1.267 g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.606
• PKA: 15.58±0.20(Predicted)
• CAS DataBase Reference: 1,4,5,6-TETRAHYDROPYRROLO[3,4-C]PYRAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4,5,6-TETRAHYDROPYRROLO[3,4-C]PYRAZOLE(769895-06-9)
• EPA Substance Registry System: 1,4,5,6-TETRAHYDROPYRROLO[3,4-C]PYRAZOLE(769895-06-9)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 769895-06-9(Hazardous Substances Data)

Usage

General Description

1,4,5,6-Tetrahydropyrrolo[3,4-c]pyrazole is a chemical compound characterized by a polycyclic structure with two fused ring systems: a pyrrole ring and a pyrazole ring. This heterocyclic compound doesn't have any available information on its physical properties such as color, state, or solubility. Being a complex organic molecule, it is likely to be a product of specialized synthetic methods in the field of organic chemistry. However, exact details regarding its use, preparation, and safety profile are currently unavailable in the public domain, suggesting that it may be primarily of interest for research purposes and may not be widely used in commercial or industrial products.

InChI:InChI=1/C5H7N3/c1-4-2-7-8-5(4)3-6-1/h2,6H,1,3H2,(H,7,8)

Upstream product

• 1280210-79-8 2,6-dihydropyrrole [3,4-c]pyrazole-5(4H)-carboxylic acid tert-butyl ester 
• 657428-42-7 4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carboxylic acid tert-butyl ester 
• 905274-02-4 tert-butyl (3Z)-3-[(dimethylamino)methylene]-4-oxopyrrolidine-1-carboxylate 

Downstream Products

• 1280210-80-1 2-(methylsulfonyl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-5-ium benzenesulfonate 
• 1226781-81-2 tert-butyl 1-(methylsulfonyl)-4.6-dihydropyrrolo[3,4-c]pyrazole-5 (1H)carboxylate 
• 1226781-82-3 tert-butyl 2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylate 
• 1226781-44-7 Omarigliptin 
• 1226781-87-8 tert-butyl {(2R,3S,5R)-2-(2,5-difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-yl}carbamate 

Relevant articles and documents

Amino tetrahydropyrane derivatives

The invention provides amino tetrahydropyrane derivatives, pharmaceutically-acceptable salts, hydrates, solvates, stereoisomers and prodrugs of the amino tetrahydropyrane derivatives, a preparation method of the amino tetrahydropyrane derivatives and a pharmaceutical composition containing the compounds. A formula (I) of the amino tetrahydropyrane derivatives is as shown in the specification. The compounds are capable of inhibiting activity of DPP-IV (dipeptidyl peptidase IV) and can be used for treating dipeptidyl peptidase IV associated diseases such as diabetes, obesity and other metabolic diseases.

Omarigliptin (MK-3102): A novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes

In our effort to discover DPP-4 inhibitors with added benefits over currently commercially available DPP-4 inhibitors, MK-3102 (omarigliptin), was identified as a potent and selective dipeptidyl peptidase 4 (DPP-4) inhibitor with an excellent pharmacokinetic profile amenable for once-weekly human dosing and selected as a clinical development candidate. This manuscript summarizes the mechanism of action, scientific rationale, medicinal chemistry, pharmacokinetic properties, and human efficacy data for omarigliptin, which is currently in phase 3 clinical development.

AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES

The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.